Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2020-04-20 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
2019年度独立董事述职报告（赵骏）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's 2019 Annual Work Report" for Betta Pharmaceuticals Co., Ltd. It details the independent director's attendance at board meetings, opinions on various company reports including annual and quarterly reports, and committee work during the 2019 fiscal year. The content focuses on the director's duties, opinions on financial and governance matters, and oversight activities rather than presenting the full financial statements or comprehensive company performance data. The document is about the independent director's report on their duties and opinions for the year, which is a type of management or board-related report rather than a full annual report or audit report. It is not a call transcript, earnings release, or regulatory filing. Given the focus on board and management activities and opinions, the best fit is Board/Management Information (MANG). The document length is 4208 characters, which is relatively short and consistent with a report or statement rather than a full annual report. Therefore, the classification is MANG with high confidence.
2020-04-20 Chinese
2019年度独立董事述职报告（汪炜）
Management Reports Classification · 95% confidence The document is titled as an "Independent Director's Annual Report for 2019" and details the independent director's activities, attendance at board meetings, opinions on company matters, committee work, investigations, investor protection efforts, and training during the 2019 period. It is a detailed report on the independent director's duties and performance over the year, which aligns with a Management Reports category rather than a general Annual Report or Audit Report. The document length is about 2045 characters, which is relatively short but contains substantive content about management oversight and governance activities. It is not a simple announcement or certification, nor is it a financial statement or earnings release. Therefore, the best fit is Management Reports (MDA).
2020-04-20 Chinese
2019年度监事会工作报告
Management Reports Classification · 95% confidence The document is titled as the "2019年度监事会工作报告" which translates to "2019 Supervisory Board Work Report" for Betta Pharmaceuticals Co., Ltd. It details the supervisory board's activities, including oversight of financial conditions, compliance with laws and regulations, internal controls, and other governance matters for the fiscal year 2019. The content includes detailed supervisory opinions on financial statements, internal controls, fundraising usage, related party transactions, and other corporate governance aspects. It is a comprehensive report on the supervisory board's work rather than a simple announcement or certification. The document length is 3869 characters, which is relatively short but contains substantive content and detailed oversight information. This type of report aligns with a Management Report (MDA) as it provides management's detailed explanation and oversight of financial results, business trends, and governance for the year. It is not an Annual Report (10-K) or Audit Report (AR) because it focuses on supervisory board activities and oversight rather than full financial statements or audit opinions alone. It is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA) because it contains substantive content rather than just an announcement or certification. Therefore, the best classification is Management Reports (MDA).
2020-04-20 Chinese
第三届监事会第四次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of 贝达药业股份有限公司 regarding their fourth meeting of the third session. It includes approvals of various reports such as the 2019 Supervisory Board Work Report, 2019 Financial Final Report, 2019 Annual Report, profit distribution plan, special report on raised funds usage, internal control self-evaluation report, and the proposal to reappoint the accounting firm. However, the document itself does not contain the full reports or detailed financial statements but refers to these reports being disclosed separately on the official disclosure website (巨潮资讯网). The document is primarily a meeting resolution announcement summarizing decisions and approvals, not the actual reports themselves. The length is 3681 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits best under Regulatory Filings (RNS) as a general regulatory announcement of meeting resolutions and approvals, not the full Annual Report (10-K) or Audit Report (AR).
2020-04-20 Chinese
2019年年度报告
Annual Report Classification · 100% confidence The document is titled '2019 年年度报告' which translates to '2019 Annual Report'. It contains detailed sections including company overview, financial data, business summary, management discussion and analysis, governance, and financial statements. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. It includes comprehensive financial figures, business operations, risk factors, and corporate governance information typical of an annual report. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2019
2020-04-20 Chinese
关于召开2019年度股东大会的通知
AGM Information Classification · 95% confidence The document is a detailed notice about the convening of the 2019 Annual General Meeting (AGM) of 贝达药业股份有限公司 (Betta Pharmaceuticals Co., Ltd.). It includes information about the meeting date, voting procedures (both onsite and online), agenda items to be discussed and voted on (including the 2019 annual report, financial statements, profit distribution plan, and other corporate governance matters), registration details for shareholders, and proxy voting instructions. The document does not contain the actual annual report or financial statements but rather serves as a formal notification to shareholders about the AGM and the matters to be considered. This fits the definition of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting, including notices and meeting details. The document length is over 5,000 characters and is comprehensive in describing the AGM logistics and agenda, confirming it is not merely an announcement of a report publication (RPA) or a regulatory filing (RNS). Therefore, the correct classification is AGM-R with high confidence.
2020-04-20 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.